For advanced NSCLC patients with EGFR-activating mutations involving deletions in exon 19 (exon 19 deletion) or a substitution mutation in exon 21, specifically Leu858Arg (L858R), EGFR-TKIs are the standard first-line therapies. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.